Recent Finacing
Recent Raise
Halia Therapeutics is a clinical-stage biopharmaceutical company in Lehi, Utah developing oral small-molecule NLRP3/NEK7 inflammasome inhibitor HT-6184 (Phase II) and LRRK2 inhibitor programs for neurodegenerative and inflammatory indications.